profit from every $100 of sales.
$0$100
Instil Bio
$6.08-2.56% today
-56.3% in 1 year
1-year low $5.571-year high $14.42
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Instil Bio sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$71.4 million of profit last year.
SalesProfit
Instil Bio vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Instil Bio | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Instil Bio's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -203 | -87 | -56 | -52 | |
| -217 | -147 | -63 | -66 | |
| -223 | -156 | -74 | -71 | |
| -34.40 | -24.00 | -11.39 | -10.70 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 482 | 326 | 264 | 204 |
| Cash | 44 | 9 | 9 | 7 |
| Total debt | 80 | 86 | 87 | 85 |
| Total liabilities | 119 | 100 | 94 | 90 |
| 364 | 226 | 169 | 114 | |
| 6 | 7 | 7 | 7 | |
| -39.8% | -38.5% | -20.4% | -26.3% | |
| -61.4% | -69.1% | -43.8% | -62.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -180 | -82 | -56 | -37 | |
| 85 | 21 | 10 | 10 | |
| -265 | -103 | -66 | -47 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 30 | 18 | 17 | 9 |
Valuation
- –
- –
- –
- 0.5×
- –
- –
- –
- -88.8%
- -173.1%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -27.6%
- -38.7%
- -39.8%
- -23.6%
- -27.6%
- –
Growth
- –
- –
- +44.3%
- –
- +5.9%
Financial health
- -0.1×
- 0.00
- 0.0%
- -9.8×
- 39.87
- 39.87
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 15%of 952
Bottom 20%of 884
Bottom 1%of 987
What analysts expect
- Average price target
- $7.00
- Range
- $7.00 – $7.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.62 | -0.62 | +0.0% |
| Mar 27, 2026 | -1.21 | -2.31 | +47.6% |
| Nov 13, 2025 | -2.01 | -2.00 | −0.5% |
| Aug 13, 2025 | -3.24 | -1.72 | −88.4% |
| May 13, 2025 | -4.32 | -2.02 | −113.9% |
| Mar 4, 2025 | -1.82 | -3.75 | +51.5% |
| Nov 13, 2024 | -3.54 | -2.08 | −70.2% |
| Aug 13, 2024 | -2.29 | -3.04 | +24.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
26No pass
Benjamin Graham
79Pass
Philip Fisher
30No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
23No pass
Terry Smith
16No pass
Questions about Instil Bio
Is Instil Bio a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Instil Bio AI analysis
What does Instil Bio do?
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). It is in Biotechnology.
Does Instil Bio pay a dividend?
No. Instil Bio does not pay a dividend at the moment.
Is Instil Bio stock halal?
No. Instil Bio does not pass our halal screen: its debt is 207% of its market value, at or above the 33% limit. How we check
How has Instil Bio stock done over the past year?
Down 56.3% over the past twelve months, to $6.08. It traded between $5.57 and $14.42 and is 57.8% below its high.
Who are Instil Bio's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Instil Bio's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.